92 results about "Immune Cell Activation" patented technology

A hydrogel particle, comprising a matrix comprising a polymerized monomer, said matrix comprising a plurality of micropores and a plurality of macropores, and one or more immunostimulatory biomolecules selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, and combinations thereof.

The invention relates to the technical field of immune cell culture, in particular to an immune cell culture data monitoring method and system based on activation analysis. When the immune cell culture equipment monitors that the signal protein is conducted on the abnormal standard signal channel, the real-time metabolic network is reduced based on the interference degree of the abnormal standard signal channel on the metabolic pathway, the metabolic enzyme concentration is calculated and analyzed, and a metabolic activity monitoring reference is generated; if it is monitored and detected in real time that unreasonable metabolism conditions exist in metabolic data of immune cell culture, peak integral deviation parameters for cell factor compensation are constructed based on the metabolic enzyme concentration deviation value of the metabolic activity monitoring benchmark to conduct injection compensation regulation and control on cell factors of the cultured immune cell sample. According to the method, the abnormal proliferation data, the abnormal proliferation-causing signal path data and the metabolic data in the immune cell culture process can be subjected to rapid and accurate activation analysis, so that the immune cell activation performance can be better optimized, and the culture quality is improved.

The invention belongs to the technical field of biological medicine, and relates to a composite polypeptide composition as well as a preparation method and application thereof. According to the technical scheme, pH responsive polymer loaded oligopeptide-1, acetyl heptapeptide-4 and palmitoyl tripeptide-1 are adopted as a core, hyaluronic acid is adopted for wrapping, a hyaluronic acid layer adsorbs palmitoyl tripeptide-8, heptapeptide-6 and decapeptide-4, and the composite polypeptide with a core-shell structure is prepared and used for treating inflammatory skin diseases. In the acute stage of inflammation, the active ingredients on the outer layer quickly inhibit the activation of proinflammatory factors and immune cells and relieve red, swollen and heat pain, and the gel outer layer formed by hyaluronic acid realizes continuous release, prolongs the action time and supplements moisture to the skin; the pH-responsive polymer of the inner layer releases active ingredients at the inflammation part, so that relapse is prevented, and the skin barrier function is repaired. The composition plays a role from multiple dimensions of inflammation regulation, barrier repair, oxidation resistance and the like through a multi-layer structure design and a multi-component synergistic effect.

Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding are described. The recombinant proteins include an extracellular domain of an inhibitory immune cell protein and an intracellular domain of a stimulatory immune cell protein connected via a transmembrane domain. The recombinant proteins can be used to stimulate immune cell activation in the fight against cancers and infectious diseases, among other uses.

The invention relates to a method for enhancing target cell removal capacity of immune cells and application. The method comprises the following steps: recombining CD58 and TP53 genes with a granzyme B gene so as to obtain recombinant genes NFAT-GZMB-CD58 and NFAT-GZMB-TP53, and meanwhile, adding a transcription factor NFAT binding site into a regulation region of the obtained recombinant genes. Then, the two recombinant genes are directionally inserted into specific gene loci of immune cells through a gene editing technology. Expression of the two recombinant genes is regulated and controlled by an immune cell activation signal pathway, and translation products of the two recombinant genes can be delivered to target cells of immune cells through a granzyme-perforin pathway, so that the scavenging capacity of the immune cells to the target cells is enhanced, and apoptosis and escape of the target cells are inhibited. The method can be applied to the field of cell therapy.

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

ROR1-specific antigen-binders, and multispecific antibodies are provided, which contains one or more ROR1-specific antigen-binding sites and at least one antigen-specific binding site for an activation receptor (such as CD3) on an immune cell, wherein various configurations are presented of new VHH-based anti-ROR1 sequences in relation to the antigen-specific binding site for the immune cell activation receptor, as well as to a scaffolding segment forming a constant region of the antibodies. These multispecific antibodies have been demonstrated to bind to ROR1-positive cancer cells, induce immune cell-mediated cytotoxicity against ROR1-positive target cells, and to inhibit growth of tumor size in animals.

The invention discloses an engineered exosome preparation with tumor targeting and specific gripper response release functions as well as a preparation method and application of the engineered exosome preparation. The preparation comprises a myocardial cell exosome, an NK cell biotinylation activation antibody, a tumor disease biotinylation antibody, streptavidin, a tumor fiber matrix FAP targeting peptide and a tumor matrix enzyme response peptide, and anchoring is carried out through an acetamide compound-polyethylene glycol anchor point platform. The engineering bispecific exosome preparation with good tumor targeting and barrier breakthrough ability and immune cell activation effect is prepared, and the preparation breaks a solid tumor compact fiber barrier and increases NK cell infiltration by utilizing the fibrosis treatment ability of the myocardial cell exosome and the capture and targeting effects of an anchor point platform; the natural killer cells are in close contact with tumor cells, the lasting tumor cell killing effect is achieved, and the tumor matrix environment is fundamentally changed.

The present invention relates to tumor-specific immune cell markers and their uses. Specifically, an immune cell marker combination is provided, comprising: (1) an immune cell activation marker, and (2) an immune cell inhibition marker, optionally further comprising (3) an intracellular marker, and / or (4) a tissue-resident memory marker. The marker combination of the present invention can more accurately identify and enrich tumor-specific immune cells, and the enriched cell population has better tumor reactivity and tumor killing function.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

A method for predicting an immune cell activation state is provided, comprising: obtaining a plurality of single immune cell images and a plurality of multiple immune cell images, each immune cell object in the plurality of single immune cell images and the plurality of multiple immune cell images being selected from a set of immune cell objects subjected to a same perturbation condition; processing the plurality of single immune cell images by using a first activation state prediction model to obtain a plurality of first activation state prediction values corresponding to the plurality of single immune cell images respectively, which are output by the first activation state prediction model; processing the plurality of multiple immune cell images by using a second activation state prediction model to obtain a plurality of second activation state prediction values corresponding to the plurality of multiple immune cell images respectively, which are output by the second activation state prediction model; and determining an activation state of the set of immune cell objects based on the plurality of first activation state prediction values and the plurality of second activation state prediction values.

The invention relates to the field of biological detection, in particular to a cell composition as well as a preparation method and application thereof. The invention provides a cell composition. The cell composition comprises effector cells and target cells, the effector cells are obtained by performing primary activation, secondary activation, culture and cell collection on PBMC cells; the first activation adopts a CD3 monoclonal antibody; in the second activation, rhIL-2, rhIL-4, rhG-CSF, rhTNF-alpha and rhIFN-gamma are adopted; the target cells are obtained after HLA high-resolution typing screening. The invention provides a method for detecting the killing activity of a human in-vitro immune cell activation preparation on tumor cells. The effectiveness of the prepared preparation for treating tumor diseases is quickly, effectively and intuitively evaluated.

The present application relates to the field of biomedical technology, and specifically to CAR molecules, CAR cells, CAR pharmaceutical compositions and their applications. The CAR molecule includes an extracellular domain, a transmembrane domain, and an intracellular domain; the extracellular domain includes an antigen binding domain and a multimerization / dimerization domain in sequence. The present application transforms the extracellular structure to improve the polymerization ability of the CAR molecule, which helps to improve the activation efficiency of CAR immune cells, promote the formation of stable and orderly immune synapses, and thus enhance the anti-tumor function of CAR immune cells.

Disclosed herein are immune cells (Bisuper Cells, BS-Cells) that have been engineered to express an immune cell activator polypeptide comprising an extracellular marker domain and incorporate the polypeptide into the cell membrane surface. Also disclosed are immune cells engineered to secrete one or more polypeptide effector molecules, and immune cells engineered to express both molecules. Nucleic acid vectors for expressing these molecules in immune cells are disclosed. Also disclosed are bispecific polypeptides that can be used to specifically bind immune cells expressing immune cell activator polypeptides to another cell. Also disclosed are systems comprising both immune cells and various bispecific polypeptides that can bind to different cell surface proteins of the same or different target cells, e.g., that can be used to expand immune cells in vivo and treat various tumors.

Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and / or potency. Also provided are methods of making and using the CACCRs described herein.

Aspects of the present disclosure include a therapeutic immune cell comprising an Antigen Receptor for Immune Cell Activation (i.e. CAR, TCR, or BiTE) and a Reverse Fate Receptor (RFR). The RFR comprises an extracellular Fas receptor domain, a transmembrane domain and an intracellular domain that transmits cytokine signaling.

Provided herein are constitutively active chimeric cytokine receptors (CACCRs). Such CACCRs allow for increased immune cell activation, proliferation, persistence, and / or potency when present on immune cells bearing chimeric antigen receptors (CARs). Also provided are methods of making and using the CACCRs described herein.

The invention discloses a TPZ / TPP-RBC-FA liposome and an application thereof in oral cancer treatment, the brand new TPZ / TPP-RBC-FA liposome is creatively provided for the technical field of oral cancer treatment for the first time, and the effectiveness of the TPZ / TPP-RBC-FA liposome in oral cancer treatment is proved through an in-vitro cell experiment and an in-vivo experiment. The TPZ / TPP-RBC-FA liposome not only can effectively induce tumor cell apoptosis, but also can cause immunogenic cell death and immune cell activation, and has a wide application prospect in clinical treatment of oral cancer.

The application provides development and application of an anti-OX40 antibody and immune cell activation, and the anti-OX40 antibody or a fragment thereof of the application has strong binding to human OX40 or Rhesus monkey OX40.

The present disclosure pertains to KIR3DL3 inhibitors (e.g., anti-KIR3DL3 antibodies or antigen-binding fragments thereof) and immune cell activating agents and uses thereof, such as to modify immune effector cells.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

Mammals rely on adaptive immunity to protect against infections and tumors, with the thymus playing a crucial role by producing T cells that target infected or cancerous cells. The thymus, however, undergoes functional decline with age, significantly impairing the immune system in the elderly. To investigate reversing this decline, compositions and methods for activation and differentiation of T cell progenitors in extrathymic tissues are disclosed that stimulate production of differentiated T cells. For example, LNP-mediated delivery of mRNAs encoding DLL-1, IL-7, and FLT3L to the liver is shown to create a temporary site for T cell maturation that enhances T cell-mediated immunity in aged mice without causing autoimmunity. This approach facilitates ectopic T cell development from hematopoietic precursors and activates dendritic cells, providing evidence that engineering adaptive immunity in vivo can effectively mitigate immune aging.

To provide multispecific B7H3 target compounds and methods for using them. [Solution] A multispecific B7H3 target compound and a method of using the same are provided. The multispecific compound includes a bispecific target protein comprising a B7H3 target domain and an immune cell binding domain; and a triplicate target protein comprising a B7H3 target domain, an immune cell binding domain and an immune cell activation domain. The method of use includes a method of inducing NK-mediated cell death, a method of inducing NK expansion in vivo, and a method of treating cancer.

The invention relates to a dual glycan modified probe for enhancing tumor immunotherapy. A dendritic polymer with alkynyl at the tail end of a branch chain is used as a carrier, and the surface of the dendritic polymer is simultaneously modified with galactose, amino, cyan-5 fluorescent dye, phenylboronic acid and methyl 4-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) butyrate. According to the treatment scheme, the prepared double glycan modified probe is subcutaneously injected into a tumor peripheral area of a tumor-bearing mouse. And the enrichment condition of the probe in a tumor area is monitored by using a fluorescence signal of cyanine 5. The dual glycan modification probe is connected to sialic acid on the surface of a tumor cell by utilizing the specific recognition effect of phenylboronic acid and sialic acid, and the sialic acid is blocked to hinder immune escape of the tumor cell. More probes are combined to the surfaces of tumor cells through ultraviolet light crosslinking of amino and methyl 4-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) butyrate, and a huge amount of galactose is introduced to promote immune cell activation, so that the aim of enhancing tumor immunotherapy is fulfilled.

The invention belongs to the technical field of biological medicine, and particularly relates to a rheumatism immune disease treatment composition combining traditional Chinese medicine active ingredients and immune regulation and application of the rheumatism immune disease treatment composition, and the rheumatism immune disease treatment composition comprises the following components in parts by weight: 10-50 parts of a traditional Chinese medicine active ingredient compound; 0.01 to 1 part of an immune regulation factor; 50 to 90 parts of pharmaceutic adjuvants; wherein the traditional Chinese medicine active component compound is prepared from the following components: astragaloside, artemisinin, curcumin and triptolide in a weight ratio of (2-5): (1-3): (1-4): (0.5-2); the immunoregulation factor is composed of recombinant human interleukin-10 (rhIL-10), a transforming growth factor-beta1 (TGF-beta1) and a CTLA4-Ig fusion protein according to a weight ratio of (1-3): (0.5-2): (1-4). The active ingredients of the traditional Chinese medicine cover a plurality of links of anti-inflammation, anti-oxidation, immunoregulation and the like, and immunoregulatory factors accurately intervene in immune cell activation and a cell factor network to jointly inhibit abnormal immune response.

Described herein are compositions and methods for modulating expression of effector molecules using engineered CCL3 promoters. Immune-responsive cells comprising the same are also described. Further wherein the engineered CCL3 promoter comprises an ablation of at least one nucleotide motif wherein the ablation increases the inducibility of the engineered CCL3 promoter in the presence of an immune cell activation signal compared to the inducibility of a wild-type CCL3 promoter in the presence of the same immune cell activation signal.

The invention relates to an application of India giant globular bacteria in preparation of a medicine for regulating a tumor microenvironment, and belongs to the technical field of biological medicines. The invention provides an application of India giant globular bacteria XA-511 in preparation of a medicine for regulating a tumor microenvironment. Researches show that the India giant globular bacteria XA-511 can be colonized in a tumor microenvironment, the tumor microenvironment can be transformed through a metabolic pathway of the India giant globular bacteria XA-511, immune cell activation enhancement and the like, and cold tumors are transformed into hot tumors, so that the treatment effect of the immunosuppressor on tumors is promoted. Furthermore, treatment of secondary tumors is more difficult than primary tumors, since tumors may be present at multiple sites, and the volume and number of tumors may vary over time. And by virtue of the characteristic of a tumor hypoxia environment, the India giant globular bacteria XA-511 can be selectively colonized at a tumor occurrence part after entering a systemic circulatory system, so that the tumor microenvironment is specifically changed, and the treatment effect of the immunosuppressor on tumors is enhanced.

The invention discloses sprayable hydrogel for tumor postoperative adhesion prevention and immunotherapy as well as a preparation method and application of the sprayable hydrogel, and belongs to the technical field of biomedical materials. The sprayable hydrogel comprises a hydrogel matrix material and a nano material dispersed in the hydrogel matrix material; wherein the nano material is an ovalbumin liposome; the hydrogel matrix material is prepared from oxidized konjac glucomannan and methacrylated gelatin. According to the sprayable hydrogel, on a biological tissue interface, one side has stable tissue adhesion capacity, and the other side keeps free from surrounding tissues; due to the asymmetric adhesion design, the unexpected adhesion problem caused by indifference adhesion of traditional hydrogel can be reduced; in addition, drug release is doubly regulated and controlled through liposome and a gel network, antigen burst release is avoided, immune cell activation is remarkably promoted, and then the tumor recurrence rate is remarkably reduced.

The present invention provides the development and application of anti-OX40 antibodies and immune cell activators, and the anti-OX40 antibodies or fragments thereof of the present invention retain relatively strong binding to human OX40 or rhesus monkey OX40.

The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and / or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.